Across TCGA pan-cancer cohorts, TCL1B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCL1B data layer compared with 16 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher TCL1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TCL1B expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

KIRP, LUAD, and SKCM are the cancer types where TCL1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.188	0.903	<.001	15	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.861	0.560	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TCL1B tumor-vs-normal RNA expression · all TCL1B data types